MAPS addresses progress in FDA discussions on MDMA-assisted therapy for PTSD and outlines regulatory steps, safety oversight, and the path toward potential resubmission

MDMA-assisted therapy for PTSD is moving through ongoing discussions between MAPS and the FDA about what evidence, safety measures, and regulatory steps would be needed for potential progress. PTSD treatment standards, trial design, therapist training, abuse potential, and post-approval monitoring are central to the conversation. MAPS frames the update around a report of progress with the FDA rather than a final regulatory decision. The focus is on how concerns from earlier review stages could be addressed through additional data, clearer risk management, and more defined clinical protocols for patient selection, session conduct, and follow-up care. The broader significance centers on whether psychedelic-assisted therapy can satisfy conventional drug approval requirements while preserving a therapy model that depends on preparation, supervised dosing, and integration. The outcome could shape future expectations for MDMA in psychiatry and for other psychedelic treatments seeking approval.